Cosopin

Quick links to important sections

Cosopin

Method of action: Antitussive Opioid

Treatment option: Cough

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cosopin

Cosopin is the brand name for a medicinal product whose active ingredient is Codeine, a substance used primarily for two distinct therapeutic actions: relieving pain and suppressing coughs. It is a narcotic analgesic and an antitussive agent, making it a prescription-only medicine with central nervous system activity.


Quick Facts: Cosopin (Codeine Composition)

Property Description
Active ingredient Codeine (Codeine phosphate)
Form Oral solution (Syrup/Linctus) or Tablet
Pharmacological class Opioid analgesic and Antitussive agent
General Purpose Relief of mild to moderate pain and cough suppression
Origin Semi-synthetic opioid (derived from Morphine)

What Type of Medicine is Cosopin, and What Does it Contain?

Cosopin contains Codeine (often as codeine phosphate hemihydrate), which is a semi-synthetic opioid derived from Morphine, a naturally occurring compound found in the opium poppy (Papaver somniferum). The medicine's dual classification stems from its ability to interact with specific receptors in the central nervous system (CNS), affecting both the body's pain perception and the cough reflex. Unlike non-opioid medications, Codeine's mechanism involves it being partially converted into the more potent active compound, Morphine, in the liver, a process mediated by the CYP2D6 enzyme. This biotransformation is involved in the substance's efficacy, particularly in managing mild to moderate pain when other analgesics may be insufficient.

What is the General Purpose of Cosopin?

The general purpose of a product containing Codeine is to provide symptomatic comfort by raising the pain threshold and calming the urge to cough. Specifically, it is utilized for pain relief and cough suppression, often used in scenarios involving persistent, dry coughs or temporary aches. Codeine acts as an antitussive, with the ability to reduce cough severity in controlled settings. The medicine has a direct action in lowering the frequency and intensity of a persistent cough. Cosopin is typically supplied for oral administration, being available as a tablet or as a liquid oral solution (sometimes referred to as a syrup or linctus), offering different forms suitable for various patient preferences.

Regulatory References

  1. Codeine Drug Information - NIH MedlinePlus

What side effects are possible with Cosopin ?

Possible Side Effects and Safety Information

The safety profile for this medicine, a combination of dorzolamide (a carbonic anhydrase inhibitor) and timolol (a beta-blocker), is derived from their known effects, including potential systemic absorption following eye drop use.

Contraindications and Restrictions

Official regulatory documents mandate that this medicine must not be used in patients with certain severe pre-existing conditions, including:

  • Reactive airway disease, such as bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease (COPD).
  • Severe heart conditions, including sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock.
  • Severe renal impairment.
  • Hypersensitivity to the active substances, to any of the excipients, or to sulfonamides.

Systemic and Serious Adverse Reactions

Since the active components may be absorbed into the bloodstream, the topical eye drop can potentially cause adverse reactions similar to those seen with oral beta-blockers or sulfonamides.

Serious reactions reported rarely include:

  • Severe respiratory reactions, such as bronchospasm (especially in patients with pre-existing asthma) and, in rare cases, death due to bronchospasm or in association with cardiac failure.
  • Cardiac events, including severe bradycardia, heart block, and cardiac failure.
  • Severe allergic and skin reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, and anaphylaxis.

Common Adverse Reactions

Adverse reactions classified as Very Common typically include burning, stinging, or discomfort in the eye. Common reactions reported include conjunctivitis, eyelid irritation, blurred vision, eye itching, and an unusual or bitter taste.

Population-Specific Safety Notes

The medicine is not recommended for use in children younger than 2 years of age, as safety and efficacy have not been established. It is contraindicated in breast-feeding women, as timolol may pass into breast milk. Caution is advised when used in patients with diabetes mellitus, due to the potential masking of the signs and symptoms of acute hypoglycemia by the beta-blocker component.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Cosopin

Overdose scope

Documented overdose presentations: An overdose is typically classified by a triad of symptoms involving the Central Nervous System (CNS) and Respiratory System. Manifestations include profound sedation progressing to coma, pinpoint pupils, and severe respiratory depression (slowed or stopped breathing). Circulatory signs such as cyanosis (bluish lips/fingernails) and severe hypotension are also documented.

Dose-related or exposure-related factors: The risk of overdose is heightened by the co-administration of Codeine with CNS depressants. Furthermore, regulatory warnings note that accidental ingestion of even small amounts in children can be fatal, and patients who are ultra-rapid metabolizers are at increased risk, as are elderly or debilitated patients.

Emergency-response statements: Immediate emergency medical attention must be sought for any suspected overdose. Emergency procedures mandated by regulatory bodies include the administration of Naloxone (an opioid antagonist) and provision of immediate breathing support (ventilation) due to the life-threatening risk of respiratory failure. Patients require close monitoring of vital signs after intervention.

When immediate medical help is required (label-derived phrasing only): Immediate emergency medical attention must be sought for any suspected overdose. Call emergency services immediately (e.g., 911) if any symptoms of overdose are suspected.

Overdose classifications (high-level)

Severity classification (as defined in official documents): Classified as having the potential for life-threatening effects, specifically fatal respiratory depression.

Regulatory basis (EMA / FDA / etc.): Based on official documentation from the U.S. Food and Drug Administration (FDA) and other international regulatory bodies.

Overdose-context constraints (as defined in official documents): Management requires close monitoring of the patient's condition and supportive treatment after specific interventions.

Resulting overdose structure

Official overdose statements:

  • Overdose presents with profound sedation leading to coma, pinpoint pupils, and life-threatening respiratory depression.
  • The required immediate action is to seek emergency medical attention and administer Naloxone, an opioid antagonist, to reverse the severe CNS effects.
  • The potential outcomes include respiratory failure and death, necessitating close monitoring and breathing support during treatment.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents explicitly define the overdose profile by focusing on the immediate physiological dangers posed by CNS and respiratory depression, which is the mechanism of toxicity. This defined risk is what compels the strict regulatory requirement to seek immediate medical attention and outlines the specific, non-advisory supportive procedures, such as ventilation and the use of the antidote, for managing the life-threatening consequences of the overdose.

Therapeutic Uses of Cosopin

What Cosopin Treats: Main Uses and Benefits

Cosopin, containing Codeine, is used to provide supportive relief across two primary symptomatic domains. It is applied in contexts where additional symptomatic support is needed, particularly when conventional non-opioid treatments are deemed insufficient for the current level of discomfort.


Relief of Mild to Moderate Acute Pain

Cosopin is primarily used for managing symptoms related to physical discomfort that is classified as mild to moderate in severity. It is generally used across domains where short-term symptom management for pain is appropriate, such as temporary musculoskeletal aches or headaches. The primary therapeutic benefit assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities.


Suppression of Persistent, Irritating Coughs

The medication is relevant in therapeutic areas involving the control of the cough reflex, used to address pronounced symptoms of a non-productive, persistent cough. This is applied when groups of symptoms appear suddenly or fluctuate, such as a relentless, dry cough that interferes significantly with sleep or routine activities. It offers symptomatic relief that helps address symptom clusters that may become intense or disruptive and contributes to easing the overall symptom load.


Summary of Symptom Domains

Symptom Domain General Therapeutic Benefit
Mild to Moderate Pain Supports general well-being during symptomatic phases by assisting with functional stability.
Irritating Cough Contributes to easing the overall symptom load by addressing intense or disruptive symptom clusters.

Eligibility and Restrictions for Use

Eligibility for Cosopin (Codeine)

The official eligibility profile for Cosopin (Codeine) is highly restrictive for specific populations based on regulatory mandates from global health authorities.

Category Official Regulatory Status
Populations for whom use is allowed Adults (18+ years) with no absolute contraindications.
Populations for whom use is not recommended Adolescents (12–18 years) with compromised respiration; pregnant patients (especially third trimester).
Populations for whom use is contraindicated All children younger than 12 years of age; all patients known to be CYP2D6 ultra-rapid metabolizers; breastfeeding women; adolescents post-tonsillectomy/adenoidectomy; patients with acute severe respiratory disease.

Age-Related Eligibility Rules

Use is contraindicated in children younger than 12 years for all indications. For pain relief, the medicine is contraindicated in adolescents younger than 18 years following tonsillectomy or adenoidectomy. Older adults may require caution due to increased sensitivity and potential organ function changes.

Condition-Specific Eligibility Rules

Absolute contraindications include a known history of hypersensitivity to codeine, acute respiratory depression, or severe asthma. Use requires caution in patients with severe hepatic or renal impairment, or with conditions that increase intracranial pressure.

Pregnancy and Lactation Eligibility Status

Codeine is contraindicated in breastfeeding women. Use during pregnancy is not generally recommended, particularly during the third trimester.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Cosopin, which contains Codeine, is defined by several official regulatory mandates across substance categories and patient populations.

Absolute Contraindication Restrictions: Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated, and a 14-day washout period is mandated before Codeine use. Due to population-specific risks, Codeine is also prohibited in individuals classified as CYP2D6 ultra-rapid metabolizers and in children younger than 12 years of age.

Pharmacodynamic Synergism: The most critical interaction risk involves Central Nervous System (CNS) depressants, including alcohol, benzodiazepines, and other opioids. Concurrent use results in additive CNS depression, elevating the risk of profound sedation and life-threatening respiratory depression. Furthermore, co-administration with serotonergic drugs (e.g., SSRIs) may result in the development of Serotonin Syndrome.

Metabolic Alteration (Pharmacokinetic): Interactions affecting the hepatic metabolism of Codeine can alter drug exposure. Concomitant use with CYP2D6 inhibitors (e.g., quinidine) may reduce the analgesic effect by decreasing the conversion of Codeine to its active metabolite, Morphine. Regulatory documents also note that CYP3A4 inhibitors and inducers complexly modify the plasma concentrations of both the parent drug and the metabolite. Codeine may also reduce the efficacy of diuretics or delay the absorption of antiarrhythmics like Mexiletine.

Mechanism of Action

Pharmacodynamic Mechanism: Dual-Pathway Modulation

Cosopt is a fixed-combination product that modulates fluid dynamics through two distinct pharmacological mechanisms.

Carbonic Anhydrase Inhibition

The component dorzolamide acts primarily within the ocular ciliary processes as an inhibitor of the carbonic anhydrase II (CA-II) enzyme. The catalytic function of CA-II is crucial for the formation of bicarbonate ions, which drive the movement of electrolytes and water. By blocking this enzyme, dorzolamide disrupts this key molecular cascade, leading to a diminished flux of fluid into the posterior chamber and a subsequent decrease in aqueous humor secretion.

Beta-Adrenergic Receptor Blockade

The second component, timolol, is a non-selective beta-adrenergic receptor antagonist. Located on the ciliary epithelium, these receptors modulate the regulatory pathways governing fluid production. Timolol’s blocking action suppresses the receptor-mediated signaling involved in fluid generation, providing a complementary mechanism that limits the rate of aqueous humor formation.

Dosage and Administration Information

How Cosopin Is Used

Cosopin, containing Codeine, is primarily administered via the oral route, available as both tablets and an oral solution. The overarching principle governing its use is that it is utilized for the shortest duration possible and at the lowest effective dose necessary to address the acute symptoms. Treatment for pain, specifically, is typically limited to a maximum duration of three days.

Standard Dosing and Frequency

Usage Purpose Usual Adult Dose Range Frequency Pattern
Analgesia (Mild to Moderate Pain) 15 mg to 60 mg Every 4 to 6 hours, as needed
Antitussive (Cough Suppression) 10 mg to 30 mg Three to four times daily

The maximum recommended daily intake for adults is generally restricted to 240 mg to 360 mg. Doses are repeated only once the 4-6 hour interval has fully elapsed.

Administration Contexts and Adjustments

To aid administration and mitigate minor gastrointestinal discomfort, the oral dose may be taken with or immediately after food or milk. Tablets are swallowed whole with water. When using the oral solution, the dose is measured using a calibrated measuring device to ensure precision.

Dose adjustments are utilized for specific patient populations. A reduced starting dose is used for older adults and for patients with renal or hepatic impairment due to altered metabolic capacities. If a dose is missed, the next dose is taken at the scheduled time; a double dose should not be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cosopin (Codeine)

Evidence for Use in Mild to Moderate Acute Pain

Research exploring the use of Codeine was applied in studies examining patient-reported outcomes related to physical discomfort in short-term, defined time interval Randomized Controlled Trials (RCTs). The research examined patient-reported outcomes describing perceived discomfort, monitoring pain intensity scores and measuring how symptoms changed over the initial few hours of observation.

The findings describe patterns observed in the studies, often focusing on Codeine when it was combined with non-opioid pain relievers. These combination studies reported measurements of how symptoms evolved in the observed populations, sometimes contrasting outcomes with those reported for the non-opioid agent alone. Furthermore, studies consistently report that a high degree of individual variability was observed in the response to the medicine, which was associated with differences in individual characteristics.

Evidence for Use in Persistent, Irritating Coughs

Codeine was evaluated in research contexts involving fluctuating or unstable symptoms, such as a persistent, non-productive cough linked to common infections. Research examined patient-reported outcomes describing perceived discomfort and physiological strain, monitoring cough frequency, cough intensity, and the urge to cough. These trials were typically short-term studies focusing on episodes where symptoms become more noticeable.

However, the findings were mixed across the available evidence base. Scientific and regulatory systematic reviews have described a lack of robust evidence related to changes in cough symptoms when Codeine was observed compared to placebo in many common acute settings, indicating certainty remains low.

Research in Specific Patient Groups (Special Populations)

Codeine was studied for its use in adults, and findings describe group patterns related to this population. Constraints on research and use in pediatric patients exist due to considerations related to metabolic variability and risk, meaning comparative evidence is lacking, and data for this group are heavily limited. Research has also explored Codeine use in older adults, but evidence quality varies across studies, and data for this group remain insufficient.

What Remains Unclear or Under-Researched

The vast majority of research that studies Codeine was conducted over very short intervals. Follow-up durations were limited, meaning long-term effects are not fully established. The evidence quality varies across studies, and many older studies focused on comparing Codeine against placebo, where comparative evidence against other active treatments is sometimes lacking. Overall, research provides insight into short-term changes, but evidence highlights what is known and what is still uncertain about the consistency and predictability of the patterns observed in the studies.

Key Studies & References

  1. Codeine: MedlinePlus Drug Information (US National Library of Medicine/NIH)
  2. Codeine linctus (codeine oral solutions): Proposal to reclassify to prescription only Public Assessment Report (UK Gov)

Frequently Asked Questions (FAQ)

Common questions about Cosopin (FAQ)


Q: How quickly should I expect to feel the effects of Cosopin?

According to official regulatory information, the active ingredient in Cosopin reaches its maximum concentration in the blood plasma about one hour after it is taken orally. The full effect for pain relief is typically observed within two hours of administration.


Q: Does Cosopin interact with common over-the-counter pain relievers?

Regulatory guidance advises that you inform your healthcare provider about all medications you take, including common over-the-counter pain relievers. While Codeine is sometimes combined with non-opioid pain relievers in specific products, it is recommended to review the combination with a healthcare professional to confirm there are no risks of overlapping effects or interactions.


Q: Can Cosopin cause dizziness or lightheadedness?

Yes, regulatory documents list dizziness and lightheadedness as common adverse effects associated with the use of Codeine. This is because the medication is a central nervous system depressant. Patients are advised to be aware of this potential side effect when the medication is used.


Q: Is it normal to feel tired during the first week of taking Cosopin?

It is normal to experience drowsiness or tiredness, known medically as somnolence or sedation, especially when starting the medication. Official product information lists these effects as common adverse reactions because the active ingredient in Cosopin acts as a central nervous system depressant.


Q: How long does Cosopin stay in your system after stopping it?

The active ingredient in Cosopin has a relatively short plasma half-life of about 2.9 hours. Based on pharmacokinetics data, the majority of the oral dose is typically eliminated by the kidneys within 24 hours of administration.


Q: Can Cosopin be taken with a multivitamin?

Regulatory guidance recommends informing your healthcare provider about all substances you are taking, including any vitamins, minerals, or herbal supplements. While a direct interaction with a standard multivitamin is uncommon, it is always advisable to review all supplements and medications with a healthcare provider.


Q: What are the early signs that Cosopin is working?

For pain relief, the analgesic effect is typically maximized, or at its peak, within two hours after you take the dose. When used for cough, studies that review the product's effectiveness often look for a noticeable reduction in the frequency and intensity of coughing episodes.


Q: Are there different strengths of Cosopin available?

Yes, official prescribing information confirms that the active ingredient, Codeine, is available in multiple tablet strengths, such as 15 mg, 30 mg, and 60 mg. Oral solution and syrup forms are also available in specified strengths.


Q: Is there a generic version of Cosopin?

Yes. While Cosopin is a brand name, the active ingredient, Codeine, is widely available. Regulatory agencies have approved and market generic versions containing Codeine.


Q: Is Cosopin an antibiotic?

No, Cosopin is not an antibiotic. According to its classification, it is categorized as an Opioid Analgesic and an Antitussive Agent. This means it is used to relieve pain and suppress coughing, not to treat bacterial infections.


Q: Are there any long-term side effects associated with Cosopin?

Official warnings note that long-term use of the active ingredient in Cosopin can lead to physical dependence. There is also a risk of developing Adrenal Insufficiency with extended use, and patients should be monitored for signs of this condition.


Q: What are the signs of a serious allergic reaction to Cosopin?

Regulatory documents list severe allergic reactions as a possibility. Signs may include difficulty breathing or swallowing, hives, rash, itching, or swelling of the face, throat, or tongue. If any serious signs occur, immediate medical assistance should be sought.


Q: Does Cosopin affect sleep patterns?

Because Codeine is a central nervous system depressant, it can cause drowsiness and excessive sleepiness. Official warnings also note that opioids may cause or worsen sleep-related breathing disorders, which can involve unusual snoring or long pauses during breaths.


Q: Does Cosopin interact with supplements like St. John's Wort?

Yes, official drug information identifies St. John's Wort as a non-prescription herbal product that may interact with Codeine. It is recommended that the use of this or any other supplement be discussed with a healthcare provider before starting Cosopin.


Q: Why is it important not to suddenly stop taking Cosopin?

In patients who have developed a physical dependence on Codeine, stopping the medication abruptly may lead to signs and symptoms of withdrawal. Official guidance notes that the discontinuation of the medicine in physically dependent patients may require professional guidance.


Q: Can I drive while taking Cosopin?

Official warnings state that Codeine may cause side effects such as drowsiness, dizziness, or lightheadedness. These effects may impair the mental and/or physical abilities necessary for tasks like driving or operating complex machinery.


Q: Does Cosopin have any known sexual side effects?

Yes, regulatory information indicates that Codeine has been associated with changes in sexual function. Reported side effects include decreased sexual desire and the inability to maintain an erection (impotence).


Q: Can Cosopin cause a dry mouth?

Yes, dry mouth is listed in regulatory documentation as a common adverse reaction for products containing Codeine.


Q: Is it necessary to take Cosopin at the exact same time every day?

The typical dosing pattern for Codeine is usually every 4 to 6 hours as needed for symptom relief. This suggests a flexible schedule guided by your symptoms rather than a rigid requirement to take the medication at the same fixed time each day.


Q: What are the precautions for people with liver disease taking Cosopin?

For patients with impaired liver function, official product information advises that caution is needed because the liver processes Codeine. A reduced starting dose is often necessary according to official guidance.


Q: Can Cosopin be crushed or split?

Official guidance advises that tablets should generally be swallowed whole. Regulatory agencies caution against crushing or splitting certain opioid tablets, as this action could compromise the drug's effectiveness or its safety profile.


Q: Is Cosopin addictive?

Yes, the official product label includes a warning that Codeine, as an opioid, carries risks of addiction, abuse, and misuse. It is recognized as a narcotic pain reliever and may be habit-forming.


Q: Can Cosopin be used long-term?

Official regulatory guidelines emphasize that Codeine should be used for the shortest duration possible. Many regulatory bodies advise that the treatment duration be kept to the shortest possible time, often limited to a few days for pain relief, to reduce risks.


Q: Do I need to avoid any specific foods or drinks while taking Cosopin?

Regulatory information indicates that most common foods do not significantly affect the absorption of Codeine, and the dose may be taken with food. However, specific product labels may advise caution or avoidance of certain items like grapefruit juice.


Q: Can older adults safely use Cosopin, or are there special concerns?

Older adults may be at a greater risk for certain side effects and are more likely to have age-related changes in organ function. For this reason, official prescribing information notes that a reduced starting dose and close monitoring may be appropriate for this population.


Q: Is Cosopin used for pain management?

Yes, one of the primary general purposes of Codeine is confirmed to be analgesia, which means the relief or management of mild to moderate pain.


Q: Is Cosopin safe to use during pregnancy?

Official regulatory documents state that the safe use of Codeine during pregnancy has not been established. It should not be used in pregnant women unless the potential benefits are determined to clearly outweigh the possible risks. Use for an extended period carries the risk of Neonatal Opioid Withdrawal Syndrome (NOWS).


Q: Are there any contraindications for using Cosopin?

Yes, official eligibility criteria outline several conditions where the product must not be used. These absolute contraindications include known hypersensitivity, acute respiratory depression, severe asthma, and for all children younger than 12 years of age.

How should Cosopin be stored and disposed of?

How to Store and Dispose of Cosopin

Official regulatory documents define specific storage and disposal requirements for Cosopin (Codeine) to ensure product stability and safety.

Required Storage Conditions

Cosopin must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original container with the cap tightly closed and protected from excessive heat, moisture, and light. To maintain stability, the oral solution should not be refrigerated or frozen.

Safety and Disposal

The medicine must be kept out of the sight and reach of children due to safety concerns. Unused or expired Cosopin must be disposed of through an authorized drug take-back program or according to local regulations; the product should not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cosopin  found in:

A-Z Index: